Revascularization by Peripheral Blood Mononuclear Cell Transplantatio
- Conditions
- Critical limb ischemia due to peripheral artery disease (critical limb ischemia) and Buerger's disease
- Registration Number
- JPRN-UMIN000029597
- Lead Sponsor
- Kumamoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Not provided
1) Patients who have severe hypersensitivity or history of side effects to aphaeresis. 2) Patients who have malignant tumor or history of malignancy within the past 3 years. 3) Patients who have experienced acute myocardial infarction, unstable angina pectoris, myocarditis or cerebral infarction within 3 months. 4) Patients with active infection. 5) Patients who are pregnant or might be pregnant. 6) Patients with proliferative diabetic retinopathy (untreated, medium-term and late proliferative retinopathy) the end of treatment example is excluded. 7) Patients with platelets less than 70,000 platelets in blood test just before apheresies. 8) Patients with less than serum albumin 2 mg/dL. 9) Patients who are judged inappropriate for this trial by their attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of skin perfusion pressure at 6 weeks after initial administration of peripheral blood mononuclear cell transplantation.
- Secondary Outcome Measures
Name Time Method